Vaxiion Therapeutics, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Jun 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 2, 2026The maintenance fee for Regulated Genetic Suicide Mechanism Compositions and Methods (US 9,045,761) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 2 fees due Aug 18 to 23, 2027 · next Aug 18
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Sep 22 US 12,741,010 Immunomodulatory & Oncolytic Minicells and Methods of Use
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,574,196 | Regulated Genetic Suicide Mechanism Compositions and Methods In force · High confidence | In force | High confidence | |
| US 9,045,761 | Regulated Genetic Suicide Mechanism Compositions and Methods In force · High confidence | In force | High confidence | |
| US 10,005,820 | Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells In force · USPTO record | In force | USPTO record | |
| US 10,919,942 | Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells In force · USPTO record | In force | USPTO record | |
| US 9,267,108 | Immunomodulatory minicells and methods of use In force · USPTO record | In force | USPTO record | |
| US 9,566,321 | Immunomodulatory minicells and methods of use In force · USPTO record | In force | USPTO record | |
| US 10,039,817 | Immunomodulatory minicells and methods of use In force · USPTO record | In force | USPTO record | |
| US 10,561,719 | Immunomodulatory minicells and methods of use In force · USPTO record | In force | USPTO record | |
| US 11,219,679 | Immunomodulatory minicells and methods of use In force · USPTO record | In force | USPTO record | |
| US 10,124,024 | Ionizing Irradiation Sterilization of Bacterial Minicell-Based Biopharmaceuticals and Methods of Use In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 14: 3 lapsed for an unpaid fee · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 3 no status recorded